ライフサイエンスコーパス: yohimbine

1 tion of the alpha(2)-adrenoceptor antagonist yohimbine.

2 leotide are unaffected in cells treated with yohimbine.

3 h anxiety disorders who were challenged with yohimbine.

4 to estimate the kinetic parameters of (11)C-yohimbine.

5 effect of F was blocked by both naloxone and yohimbine.

6 healthy subjects following administration of yohimbine.

7 the alpha 2 adrenergic selective antagonist yohimbine.

8 cipitated by the alpha 2-receptor antagonist yohimbine.

9 , and to compare these effects with those of yohimbine.

10 d by cues or by the pharmacological stressor yohimbine.

11 ing were not modulated by hydrocortisone and yohimbine.

12 .4 +/- 5 muM with addition of the antagonist yohimbine.

13 by pharmacological challenge with unlabeled yohimbine (0.3 mg/kg).

14 bjects (n = 10), following administration of yohimbine (0.4 mg/kg) or placebo in a randomized, double

15 r injections of the pharmacological stressor yohimbine (0.5-2 mg/kg) or pellet priming (1-4 noncontin

16 Selective alpha2-adrenoceptor blockade with yohimbine (0.6-1.0 mg/kg i.v.) or rauwolscine (1.0 mg/kg

17 alpha 2-antagonists, idazoxan (1 microM) and yohimbine (1 microM).

18 demonstrated that systemic administration of yohimbine (1.0 mg/kg) facilitated a long-term decrease i

19 the alpha(2)-adrenergic receptor antagonist, yohimbine (1.0 microm), and attenuated by the alpha(2)-a

20 alpha(2)-adrenergic autoreceptor antagonist, yohimbine (1.0 microM), caused an increase in the oxidat

21 cited by administration of the a2 antagonist yohimbine (1.25 mg/kg, i.p.) or by environmental conditi

22 ) 5 mM BH(4) + adrenoreceptor blockade (5 mM yohimbine + 1 mM propranolol).

23 ment with the alpha2 adrenoceptor antagonist yohimbine (10 micro M), and occluded partially by the al

24 e occurs within 12 h of exposure of cells to yohimbine (100 microM), and by 48 h tyrosinase activity

25 were reversed by phentolamine (3 microM) or yohimbine (100 nM), but not propranolol (10 microM), whe

26 ciated with pellet delivery (pellet cue), or yohimbine (2 mg/kg, a pharmacological stressor).

27 hock stress and the pharmacological stressor yohimbine (2 mg/kg, i.p.) induce reinstatement of nicoti

28 osing animals to a pharmacological stressor, yohimbine (2.5 mg/kg, i.p.), alone and in combination wi

29 Pretreatment with yohimbine (2mg/kg, i.p.) enhanced the shaking induced by

30 The alpha(2) receptor antagonist, yohimbine (3 microg/microl, icv) also prevented the decr

31 Yohimbine (3 microgram/5 microliter, icv, n=8) pretreatm

32 However, i.c.v. pretreatment with yohimbine (30 microg) had no effect on improgan antinoci

33 iloride analogues on the dissociation of [3H]yohimbine, [3H]rauwolscine, and [3H]RX821002.

34 blocked by the alpha-2 adrenergic antagonist yohimbine, 5 mg/kg, i.p.; that of F by the opioid antago

35 1.7 nM), MK-912 (4.8 nM), BRL-44408 (15 nM), yohimbine (63 nM), ARC-239 (540 nM), prazosin (4900 nM),

36 ment with the alpha 2-adrenergic antagonist, yohimbine (8 micrograms, I.C.V.), blocked the attenuatin

37 Yohimbine, a natural indole alkaloid and a nonselective

38 selective alpha1-adrenergic antagonist, and yohimbine, a selective alpha2-adrenergic antagonist, als

39 dy from this laboratory suggested that (11)C-yohimbine, a selective alpha2-adrenoceptor antagonist, i

40 Yohimbine, a specific alpha2-adrenergic antagonist, comp

41 The alpha2-adrenoreceptor antagonist yohimbine abolished CSH-induced enhancement of NE inhibi

42 ggesting that an intact cell is required for yohimbine action.

43 These findings suggest that yohimbine acts through an as yet unidentified signaling

44 a concise, enantioselective synthesis of the yohimbine alkaloids (-)-rauwolscine and (-)-alloyohimban

45 arrangements of the core stereotriad of the yohimbine alkaloids from a common intermediate.

46 treatment with a combination of BIBP3226 and yohimbine almost completely antagonized the NPY-mediated

47 -arginine or the combination of prazosin and yohimbine alone did not affect the diameter of tracheal

48 nd thus habitual), whereas hydrocortisone or yohimbine alone have no such effect.

49 al study, we administered hydrocortisone and yohimbine-alone or in combination-to manipulate the acti

50 ist) antinociception was blocked not only by yohimbine (alpha 2-antagonist) but also by PACPX (A1-ant

51 X (A1-antagonist), respectively, but also by yohimbine (alpha 2-antagonist).

52 stration of terazosin (alpha(1)-antagonist), yohimbine (alpha(2)-antagonist), phentolamine (non-selec

53 be reversed by intrathecal administration of yohimbine (alpha-2-adrenoceptor antagonist).

54 a receptor blockers prazosin (alpha1) and/or yohimbine (alpha2).

55 Yohimbine also enhanced the inhibitory effect of F.

56 s tested in these two brain areas; prazosin, yohimbine, amphetamine, SKF 38393 and SCH 23390 had no e

57 Yohimbine (an alpha 2 antagonist) microperfusion into th

58 zosin (an alpha(1)-adrenoceptor antagonist), yohimbine (an alpha(2)-adrenoceptor antagonist) and phen

59 r injections of the pharmacological stressor yohimbine (an alpha-2 andrenoceptor antagonist) or pelle

60 Preinjection of yohimbine, an alpha 2-adrenergic antagonist, completely

61 zosin, an alpha 1-adrenergic antagonist, nor yohimbine, an alpha 2-specific antagonist, was as effect

62 Yohimbine, an alpha(2)-adrenoeceptor antagonist, did not

63 aggregation, which was further inhibited by yohimbine, an alpha(2A)-adrenergic receptor antagonist.

64 nts with rat subjects examined the effect of yohimbine, an alpha-2 adrenergic autoreceptor antagonist

65 Yohimbine, an alpha2 adrenergic receptor antagonist, is

66 an alpha1-antagonist, but was unaffected by yohimbine, an alpha2-antagonist.

67 As anticipated, yohimbine, an inhibitor of alpha(2)ARs, blocked this pot

68 ructure-activity relationship study of novel yohimbine analogues identified amino esters of yohimbic

69 Methiothepin, yohimbine and cyanopindolol also blocked 5-CT-stimulated

70 The alpha2-AR antagonists yohimbine and idazoxan reduced clonidine's effect on V1/

71 ist WB4101, alpha(2) adrenoceptor antagonist yohimbine and mu-opioid receptor antagonist naltrexone f

72 gnificant difference in memory score between yohimbine and placebo groups.

73 s were blocked by previous administration of yohimbine and propranolol.

74 ng of the most efficacious inverse agonists, yohimbine and rauwolscine, was 1.7- and 2.1-fold weaker.

75 All effects of NA were blocked by yohimbine and synaptic transmission was reduced by cloni

76 In MSA patients, the pressor response to yohimbine and the decrease in SBP with 1 mg/min trimetha

77 group as a whole (subjects who had received yohimbine and those who had received placebo) and for th

78 eptor agonist, UK 14,304 (1.0 microm), while yohimbine and UK 14,304 had little effect in MV; (v) coc

79 amethonium (300 microM), but were reduced by yohimbine and usually blocked by the further addition of

80 ranolol), alpha-adrenergic (phentolamine and yohimbine), and nitric oxide (NG-monomethyl-L-arginine,

81 HCl, 50 mM caffeine, and 1 mM each nicotine, yohimbine, and strychnine, plus a number of non-alkaloid

82 and oral administration of LY2817412 reduced yohimbine- and cue-induced reinstatement in both sexes.

83 Yohimbine- and pellet-priming-induced reinstatement was

84 Yohimbine antagonized the clonidine-mediated adenylyl cy

85 Support for the use of yohimbine as a fully translational tool, however, is hin

86 ing extensive evidence supporting the use of yohimbine as a safe, titratable pharmacological agent fo

87 The results provide moderate support for yohimbine as a therapeutic augmentation strategy for exp

88 Yohimbine augmentation, relative to placebo augmentation

89 was pretreated with alpha2-receptor blocker, yohimbine, before injection of alphaMNE.

90 positron emission tomography (PET) of [(11)C]yohimbine binding in brain to quantify the density and a

91 The maps of (11)C-yohimbine binding to alpha2 adrenoceptors in human brain

92 However, two sequential doses of yohimbine blocked LH-induced antinociception on both tes

93 Treatment of melanocyte cultures with yohimbine blocks the increase in tyrosinase activity by

94 ments performed using the alpha 2-antagonist yohimbine confirmed that the effects of UK were mediated

95 ximately 60%, and the effect was reversed by yohimbine, confirming that it was mediated by activation

96 s reproduced by clonidine and antagonized by yohimbine, consistent with contribution of alpha2 adrene

97 potency: cyanopindolol >/= methiothepin >>> yohimbine, consistent with rat 5-HT(1B) receptor pharmac

98 ductase pair in Gentianales: heteroyohimbine/yohimbine/corynanthe C3-oxidase (HYC3O) and C3-reductase

99 It was found that peripheral or intra-BSTv yohimbine did increase anxiety-related behavior in postp

100 Preapplication of naloxone and yohimbine did not block the interaction.

101 wever, Experiments 3 and 4 demonstrated that yohimbine did not eradicate the original fear learning:

102 30%, whereas alpha(2)-adrenergic antagonist, yohimbine, did not prevent the stimulatory effects of NE

103 ect of competition between two amilorides on yohimbine dissociation also was explored.

104 The estimated maximal increase in the [3H]yohimbine dissociation rate caused by the 5-N-alkyl amil

105 ation of a melanosome-enriched fraction with yohimbine does not cause a lowering of tyrosinase activi

106 Tyrosinase inhibition by yohimbine does not involve a decrease in substrate avail

107 results of western immunoblotting show that yohimbine does not significantly lower the amount of tyr

108 Yohimbine dose-dependently decreased advantageous respon

109 L-allylglycine, sodium lactate infusions or yohimbine elicits panic-like responses (i.e., anxiety, t

110 n with anxiety disorders, as demonstrated by yohimbine-exacerbated anxiety.

111 s confirm the usefulness of the tracer (11)C-yohimbine for mapping alpha2 adrenoceptors in human brai

112 n order of inverse efficacy of rauwolscine > yohimbine > RX821002 > MK912, whereas phentolamine and i

113 In glabrous skin, yohimbine had no effect on an equivalent thermal inflamm

114 [(35)S]GTPgammaS binding by themselves while yohimbine had weak partial agonist activity.

115 lity since tyrosine uptake studies show that yohimbine has no effect on the amount of tyrosine enteri

116 Yohimbine has not yet been investigated in the augmentat

117 xiety disorder were randomized to placebo or yohimbine HCl (10.8 mg) 1 hour before each of four expos

118 cts each received an intravenous infusion of yohimbine hydrochloride (0.4 mg/kg), m-CPP (1.0 mg/kg),

119 Yohimbine hydrochloride produces marked behavioral and c

120 ical manipulation of alpha2ARs revealed that yohimbine hydrochloride, an alpha2AR antagonist, increas

121 caine-seeking triggered by either cocaine or yohimbine in behaviorally extinguished animals with a hi

122 caine-seeking triggered by either cocaine or yohimbine in behaviorally extinguished animals with a hi

123 Presence of a blunted GH response to yohimbine in children with anxiety disorders is reminisc

124 ptor availability by means of PET with (11)C-yohimbine in healthy male adults.

125 nt difference in brain metabolic response to yohimbine in patients with PTSD compared with healthy su

126 ced norepinephrine release in the brain with yohimbine in patients with PTSD.

127 mpled arterial blood to measure intact (11)C-yohimbine in plasma.

128 ease as the alpha(2)-adrenoceptor antagonist yohimbine increased the probability of occurrence of NCT

129 ered either the alpha2-adrenergic antagonist yohimbine (increasing noradrenergic stimulation), hydroc

130 ion in activity when incubated directly with yohimbine, indicating that the drug does not act as a di

131 Moreover, yohimbine-induced cocaine-seeking behavior is BNST-depen

132 The yohimbine-induced decrease in tyrosinase activity is rev

133 Our results demonstrate yohimbine-induced depression of excitatory transmission

134 Recent studies show yohimbine-induced drug-seeking behavior is attenuated by

135 Yohimbine-induced enhancement of sympathetic tone in pat

136 Dorsal mPFC light delivery attenuated yohimbine-induced Fos immunoreactivity and disrupted neu

137 e ex vivo effects are paralleled in vivo, as yohimbine-induced impairment of cocaine-CPP extinction i

138 s, the CORT-treated rats tended to have more yohimbine-induced impulsive responses at low doses on th

139 Yohimbine-induced impulsivity on the 5CSRTT and biochemi

140 of mifepristone on maintained responding and yohimbine-induced increases in responding for ethanol an

141 In contrast, baseline consumption, yohimbine-induced increases in responding, and circulati

142 rBNI injected locally into the BLA prevented yohimbine-induced nicotine CPP reinstatement without aff

143 ortex and the caudate nucleus with high-dose yohimbine-induced norepinephrine release, but low levels

144 (42%) of the patients with PTSD experienced yohimbine-induced panic attacks and had significantly gr

145 Yohimbine-induced panic attacks tended to occur in diffe

146 e groups of rats and animals were tested for yohimbine-induced reinstatement and corticosterone relea

147 the effect of the NK1R antagonist L822429 on yohimbine-induced reinstatement of alcohol or cocaine se

148 The yohimbine-induced reinstatement of alcohol seeking was p

149 The yohimbine-induced reinstatement of alcohol seeking was p

150 istar rats, we found that L822429 attenuates yohimbine-induced reinstatement of alcohol seeking, but

151 -specific microinjections, LY2817412 reduced yohimbine-induced reinstatement of alcohol-seeking when

152 We observed a similar suppression of yohimbine-induced reinstatement of cocaine seeking by L8

153 e also observed a significant attenuation of yohimbine-induced reinstatement of cocaine-seeking after

154 infusions into the central amygdala (CeA) on yohimbine-induced reinstatement of ethanol- and sucrose-

155 BLA) mifepristone administration suppressed yohimbine-induced reinstatement of ethanol-seeking, whil

156 rtant role in the effects of mifepristone on yohimbine-induced reinstatement of ethanol-seeking.

157 Dorsal mPFC light delivery attenuated yohimbine-induced reinstatement of food seeking in eNpHR

158 ctivated GFP-negative mPFC neurons following yohimbine-induced reinstatement of food seeking.

159 ucrose, and attenuated cue-, footshock-, and yohimbine-induced reinstatement.

160 nduced reinstatement of food seeking but not yohimbine-induced reinstatement.

161 Higher dosage of yohimbine inhibited the baseline expression of bFGF.

162 ggests that alpha 2-adrenoceptors blocked by yohimbine injected I.C.V. do not appear to have a tonic

163 Assignment of the IRE-yohimbine interaction as the origin of this effect was s

164 Because yohimbine is a weak 5HT1A receptor agonist, other groups

165 adrenergic receptor (alpha(2)-AR) antagonist yohimbine is a widely used tool for the study of anxioge

166 lo[2,3-alpha]quinolizidine skeleton found in yohimbine is described.

167 ise, cannabinoids, estradiol, dexamethasone, yohimbine, losartan, dopamine, and MDMA, along with the

168 Preclinical and clinical trials suggest that yohimbine may augment extinction learning without signif

169 and demonstrate that some of the actions of yohimbine may be directly dependent upon orexin signalin

170 allel preclinical and clinical assessment of yohimbine, methodological assessment of neurochemical sy

171 y produced by morphine was reduced by either yohimbine, methysergide or atropine.

172 neither the alpha(2)-adrenoceptor antagonist yohimbine nor the alpha(1)-adrenoceptor antagonist WB410

173 The calculated log affinities at the yohimbine-occupied receptor ranged from 1.75 for 5-(N-et

174 The increase in affinity found at the yohimbine-occupied receptor was not correlated with incr

175 itro, the effects of the alpha(2) antagonist yohimbine on improgan antinociception were presently stu

176 failure (PAF), we studied the effect of oral yohimbine on seated systolic blood pressure (SBP), the e

177 rebroventricular application of atipamezole, yohimbine or BRL-44408 blocked the protection of dexmede

178 avenous infusions of the noradrenergic agent yohimbine or by direct injections of NMDA into the DMH.

179 red maternal behavior after BSTv infusion of yohimbine or idazoxan cannot both be readily explained b

180 d in postpartum rats after administration of yohimbine or idazoxan.

181 derlie the disrupted mothering of dams given yohimbine or idazoxan.

182 slides, subjects received either intravenous yohimbine or intravenous placebo in a double-blind rando

183 d when the alpha(2)-adrenoceptor antagonists yohimbine or rauwolscine were co-administered, suggestin

184 a2 adrenoceptor antagonists, atipamezole or yohimbine, or an a2A adrenoceptor antagonist, BRL-44408.

185 ortisone, the alpha2-adrenoceptor antagonist yohimbine, or both before they were trained in two instr

186 with propranolol, but neither phentolamine, yohimbine, or L-NMMA altered this response.

187 Tv) with the alpha2-autoreceptor antagonist, yohimbine, or the more selective alpha2-autoreceptor ant

188 and 15 normal comparison children were given yohimbine orally (0.1 mg/kg).

189 We find that, as with yohimbine, orexin A depression of excitatory transmissio

190 Here, we investigated yohimbine-orexin interactions.

191 lcohol were exposed to predator odor (TMT) + yohimbine over 5 consecutive days or left undisturbed.

192 rcise (end fear), such that the advantage of yohimbine over placebo was only evident among patients w

193 We previously demonstrated that yohimbine paradoxically depresses excitatory transmissio

194 tricyclic antidepressants are combined with yohimbine (Pausinystalia yohimbe); potentiation of oral

195 sure to forskolin, isoproterenol, clonidine, yohimbine, pertussis toxin, and the NO donor spermine-NO

196 After yohimbine plus cue reinstatement, the actions of CRF-R2

197 In contrast, intrathecal (i.t.) yohimbine pretreatment (30 microg) completely blocked th

198 Systemic yohimbine pretreatment (4 mg/kg, i.p.) completely blocke

199 other group of seven subjects, administering yohimbine prior to phentolamine resulted in similar find

200 Solutions of yohimbine + propranolol (Y + P), bretylium tosylate (BT)

201 While the alpha2-antagonists, yohimbine, rauwolscine and idazoxan blocked NE-induced i

202 classic alpha2 receptor antagonists, such as yohimbine, rauwolscine, and atipamezole.

203 i) UK 14,304 constricted MV but not MA while yohimbine reduced constrictions in MV but not MA.

204 ombined administration of hydrocortisone and yohimbine reduced the sensitivity of the orbitofrontal a

205 odent and human studies involving the use of yohimbine relevant to alcohol research.

206 lactate infusions or the noradrenergic agent yohimbine reliably induce panic attacks in humans with p

207 taneous administration of hydrocortisone and yohimbine renders instrumental behavior insensitive to t

208 013) and 15% (P=0.004) with phentolamine and yohimbine, respectively.

209 Yohimbine resulted in a significant increase in anxiety

210 h the alpha-2 adrenergic receptor antagonist yohimbine results in a marked down-regulation of tyrosin

211 BSTv infusion of idazoxan did not reproduce yohimbine's anxiogenic effects and anxiety was not reduc

212 arth of studies examining sex differences in yohimbine's mechanistic actions.

213 Yohimbine selectively elevates self-rated anxiety in chi

214 ecifically, amino ester 4n, in comparison to yohimbine, showed a 6-fold higher ADRA1A/ADRA2A selectiv

215 Yohimbine-stimulated Deltamax growth hormone (GH) for ch

216 Intravenous or i.c.v. pretreatment with yohimbine, the alpha2-adrenoceptor and 5-HT1A receptor a

217 Pretreatment with yohimbine, the alpha2-adrenoceptor antagonist (8 microg;

218 yrosinase activity is markedly suppressed by yohimbine, the compound has no effect on cell proliferat

219 lpha 2-adrenoceptor antagonists idazoxan and yohimbine, the noradrenaline-depleting drug reserpine an

220 In the presence of yohimbine, the rate of biosynthesis of ferritin in a cel

221 ected by the alpha 2-adrenoceptor antagonist yohimbine, the serotonergic receptor antagonist methyser

222 C) was also assessed owing to the ability of yohimbine to activate the hypothalamic-pituitary-adrenal

223 lly specific attenuation of fear produced by yohimbine transferred to another extinguished conditiona

224 Except for saline placebo and yohimbine-treated animals, comparable increases in coron

225 Yohimbine treatment facilitated extinction in 129S1, but

226 ended training, as well as d-cycloserine and yohimbine treatment.

227 , and alpha2-adrenergic receptor antagonist (yohimbine; used as a pharmacological stressor).

228 The natural product yohimbine was found (based on gel mobility shifts) to bl

229 The SBP response to yohimbine was greater in patients with MSA than in those

230 Yohimbine was uniformly well tolerated, and it behaviora

231 In the present study, yohimbine was used as a probe of noradrenergic activity,

232 Although the actions of yohimbine were not mimicked by the norepinephrine transp

233 Beneficial effects for yohimbine were readily evident for self-report measures

234 The results suggest that yohimbine, when administered in the presence of a neutra

235 wing administration of the beta 2-antagonist yohimbine, which stimulates brain norepinephrine release

236 We recorded the distribution of (11)C-yohimbine with 90-min dynamic PET and sampled arterial b

237 r antagonists has been identified based upon yohimbine, with SAR studies resulting in a 1000-fold inc

238 initial administration of clonidine (CLO) or yohimbine (YHO).

239 tion of the alpha(2)-adrenoceptor antagonist yohimbine (YO) activates the HPA stress axis and promote

240 The alpha2 adrenoceptor antagonist yohimbine (YO) increases transmitter release from adrene

241 The alpha2-adrenoceptor antagonist yohimbine (YOH) was injected i.p. or perfused locally in

242 Yohimbine (Yoh, alpha(2)-adrenoceptor antagonist) or BIB